The US Food and Drug Administration (FDA) has approved a 15-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease in infants and children.
MSD's newly approved vaccine is the first pneumococcal conjugate vaccine approved in almost a decade.
Clinical data on which the approval decision is based demonstrated an equivalent immune response for all serotypes common to the 13-valent (PCV13) vaccine after a four-dose series and better responses against the important serotype 3 and the unique 22F and 33F serotypes compared to from PCV13.
The new vaccine is currently indicated for active immunization to prevent invasive disease caused by Streptococcus pneumo...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
